

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10520372	
	Filing Date		2006-01-09	
	First Named Inventor	Asim Kumar Ray		
	Art Unit			
	Examiner Name			
Attorney Docket Number		133087.09801		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to **add** additional U.S. Patent citation information please click the **Add** button.

[Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to **add** additional U.S. Published Application citation information please click the **Add** button.

[Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	0247456	WO		2002-06-20	SmithKline Beecham Corporation		<input type="checkbox"/>
	2	04087680	WO		2004-10-14	Taisho Pharm.		<input type="checkbox"/>
	3	2004315511	JP		2004-11-11	Taisho Pharm.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10520372
Filing Date	2006-01-09
First Named Inventor	Asim Kumar Ray
Art Unit	
Examiner Name	
Attorney Docket Number	133087.09801

4	9720823	WO		1997-06-12	Novartis AG	<input type="checkbox"/>
5	0404726	WO		2004-01-15	AstraZeneca AB	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Jarvest et al., "Conformational restriction of methionyl tRNA synthetase inhibitors leading to analogues with potent inhibition and excellent gram-positive antibacterial activity," Bioorg Med Chem Lett (2003) 13(7):1265-1268.	<input type="checkbox"/>
	2	Giardina et al., "Structure-activity relationships in prazosin-related compounds. 2. Role of the piperazine ring on alpha-blocking activity," J Med Chem (1993) 36:690-698.	<input type="checkbox"/>
	3	Notice of copending applications.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button [Add](#)

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.